ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionQualitative exit interviews with people who recently completed a clinical trial can provide in-depth insights into their treatment experience and the benefits they consider most meaningful. The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
methodsInterviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial. Interviews were conducted by telephone or web-based conference using a semi-structured interview guide. The interviews were transcribed and analyzed following a content analysis approach.
resultsIn total, 147 people were invited to participate in exit interviews across 10 US trial sites. A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide. Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%). Some also noted improvement in conditions other than T2D, including joint pain/osteoarthritis (18.9%) and sleep apnea (8.1%). Nearly all participants said these treatment-related changes were meaningful. Participants described improvements in quality of life and daily activities associated with treatment. The most commonly reported adverse event was nausea (28.4%). Most participants said they would be very likely (77.0%) or likely (16.2%) to recommend their treatment to others.
conclusionsExit interview results indicate that self-reported treatment benefits were important to people who received long-term treatment with dulaglutide or tirzepatide.
Indexed as
Identifiers
42754765What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.